Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Amag to Buy Allos Therapeutics in All-Stock Deal

By Pharmaceutical Processing | July 20, 2011

Amag Pharmaceuticals Inc. said Wednesday it will buy drugmaker Allos Therapeutics Inc. for stock valued at about $268 million in a deal designed to bolster their commercial portfolio and cut costs.

Amag, based in Lexington, Mass., makes Feraheme for the treatment of iron deficiency anemia in adults with chronic kidney disease. Allos, based in Westminster, Colo., produces the T-cell lymphoma treatment Folotyn.

The companies estimate that they can save between $55 million and $60 million annually by eliminating costs, most of which will be realized in the first fiscal year after the deal closes.

Costs tied to the deal should total between $35 million and $38 million.

The boards of both companies have approved the deal, which is expected to close in the fourth quarter.

Under terms of the deal, Allos stockholders will get 0.1282 shares of Amag stock for each share of Allos.

Amag shareholders will own about 61 percent of the combined company, while Allos stockholders will have 39 percent.

Amag will nominate five of the nine members of the new company’s board, and its CEO, Dr. Brian J.G. Pereira, will serve as CEO of the new company. Amag Chairman Michael Narachi will retain his role as well.

The combined company will be based in Lexington, Mass., and probably will be renamed at a later date.

Shares of Allos fell 12 cents to $1.94 in late trading while Amag shares fell $2.76, or 14.5 percent, to $16.31.

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE